## EQUITY FUNDING
191 Deals • 170 Companies

### TOTAL FOR 2015
$1,182,353,573

### Funding by Sector
- **TECH**
  - 2015: $516,349,339
  - 2014: $583,768,091
  - 2013: $55,951,274
- **LIFE SCIENCE**
  - 2015: $583,768,091
  - 2014: $186,756,355
  - 2013: $74,241,324
- **CLEANTECH**
  - 2015: $26,284,869
  - 2014: $55,951,274
  - 2013: $26,284,869
- **ADVANCED MANUFACTURING & MATERIALS**
  - 2015: $55,951,274
  - 2014: $9,814,775
  - 2013: $10,250,000

### Funding by Top Cities/Region
- **Triangle Region**: $881,932,658
- **Durham**: $300,345,398
- **Charlotte**: $269,847,648
- **RTP**: $242,573,940
- **Raleigh**: $116,532,706

### Funding by Deal Size
- **≤ $999K**: $27M
- **$1M-4.9M**: $145M
- **$5M-14.9M**: $169M
- **$15M-29.9M**: $237M
- **$30M-49.9M**: $179M
- **≥ $50M**: $425M
# Equity Deals

## Total # of Equity Deals

191

## # of Companies Completing Deals

<table>
<thead>
<tr>
<th>Category</th>
<th>Q1</th>
<th>Q2</th>
<th>Q3</th>
<th>Q4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Life Science</td>
<td>52</td>
<td></td>
<td>12</td>
<td></td>
</tr>
<tr>
<td>Advanced Manufacturing &amp; Materials</td>
<td>12</td>
<td></td>
<td></td>
<td>8</td>
</tr>
<tr>
<td>Tech</td>
<td>98</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cleantech</td>
<td>8</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## Deals and Companies Completing Deals

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Deals</th>
<th>Companies</th>
<th>Total Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q1</td>
<td>49</td>
<td>46</td>
<td>$223,186,800</td>
</tr>
<tr>
<td>Q2</td>
<td>49</td>
<td>46</td>
<td>$227,291,200</td>
</tr>
<tr>
<td>Q3</td>
<td>53</td>
<td>46</td>
<td>$441,093,974</td>
</tr>
<tr>
<td>Q4</td>
<td>40</td>
<td>32</td>
<td>$290,781,599</td>
</tr>
</tbody>
</table>

## Funding by Category

<table>
<thead>
<tr>
<th>Category</th>
<th>Q1</th>
<th>Q2</th>
<th>Q3</th>
<th>Q4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tech</td>
<td>$55,537,746</td>
<td>$65,784,161</td>
<td>$308,377,577</td>
<td>$86,649,855</td>
</tr>
<tr>
<td>Life Science</td>
<td>$132,076,554</td>
<td>$149,957,039</td>
<td>$112,244,037</td>
<td>$189,490,461</td>
</tr>
<tr>
<td>Adv. Man. &amp; Mat.</td>
<td>$23,900,000</td>
<td>$10,350,000</td>
<td>$16,099,991</td>
<td>$5,601,283</td>
</tr>
<tr>
<td>Cleantech</td>
<td>$11,672,500</td>
<td>$1,200,000</td>
<td>$4,372,369</td>
<td>$9,040,000</td>
</tr>
</tbody>
</table>
INVESTORS

146 UNIQUE INSTITUTIONAL INVESTORS

REGIONAL BREAKDOWN

Northeast 34
Mid-Atlantic 7
Southeast 51
Midwest 10
Northwest 4
California 24
International 16

INTERNATIONAL BREAKDOWN

China 3
Israel 3
UK 2
Singapore 2
Germany 1
France 1
Ireland 1
Belgium 1
Saudi Arabia 1
Thailand 1

INTERNATIONAL BREAKDOWN

International 16
HIGHLIGHTS

MAXPOINTE®  VTV
NYSE: MXPT  NASDAQ: VTVT

Salix Pharmaceuticals, Inc.
sprout pharmaceuticals
Scioderm
Bronto
ANSIBLE
Cardioxyl Pharmaceuticals
ai AUTOMATED INSIGHTS
nContact™

24 EXITS IN 2015

The Innovators Report is made possible by generous gifts to the CED Annual Fund. Thank you to our many supporters! For more information on how to contribute, please visit www.cednc.org/donate.

REPORT SOURCES: CED, National Venture Capital Association (NVCA), North Carolina Biotechnology Center, EY, PwC, SBIR.gov